Loading clinical trials...

COMPLETEDNA

Evaluation of the Efficacy of Digital Breast Tomosynthesis Imaging

Multi-center Case Collection Study to Create a Library of Images From Various Approved FFDM Systems and 3D Images From Siemens Inspiration Digital Breast Tomosynthesis (DBT) System for Studies in Support of the Inspiration DBT Approval

NCT01373671•Siemens Medical Solutions USA - CSG

View on ClinicalTrials.gov

Summary

The primary objective of this protocol is to collect the 2-dimensional (2D) screening and diagnostic images, and 3-dimensional (3D) Digital Breast Tomosynthesis (DBT) scans from patient mammography examinations acquired on various commercially available Full Field Digital Mammography (FFDM) systems and the Siemens Inspiration DBT system, respectively.

Detailed Description

The image collection includes FFDM images and both raw and presentation data from the DBT system. The FFDM mammograms are performed using standard care screening or diagnostic mammography from various commercially available FFDM systems. All DBT images are acquired on the Inspiration DBT system specifically for the study, in addition to the clinically indicated screening mammograms. DBT images are read at the clinical sites and any DBT findings were investigated according to standard care.

Eligibility

Age

30 - No limit years

Sex

FEMALE

Healthy Volunteers

Yes

Inclusion Criteria

•All subjects enrolled into the collection study must:
•Provide signed informed consent after receiving a verbal and written explanation of the purpose and nature of the study
•be females, 40 years of age or older at the screening mammographic evaluation or age 30 or older presenting for a biopsy and have one of the following mammograms:
•o Normal cases at screening (BI-RADS® 1, 2 and 3):
•* have a screening mammogram that includes the four standard screening views (RCC, RMLO, LCC and LMLO), as well as have both MLO and CC DBT scans of each breast,
•o Actionable cases at screening (BI-RADS® 0, 4 or 5) with final BI-RADS® 1, 2, 3, 4 or 5:
•* have a screening mammogram with four SSVs and any clinically necessary diagnostic mammographic views, such as straight lateral projections, rolled, magnification view and spot compression views, and, both MLO and CC DBT scans of each breast plus 4 SSVs repeated at the diagnostic or biopsy visit if the screening images are unavailable or were acquired more than 45 days prior to DBT acquisition,
•have supporting ground-truth documentation for the final BI-RADS® assessment as follows:
•* A one (1) year FFDM follow up without evidence of cancer for normal cases not undergoing biopsy
•* A six (6) or twelve (12) month FFDM follow up confirming benign status for biopsy proven benign cases
+1 more criteria

Exclusion Criteria

•Subjects with any of the following conditions or who have had the following procedures will be excluded from this study:
•Pregnant women or women who believe they may be pregnant or are trying to become pregnant.
•Mastectomy patients
•Subjects who have had lumpectomy ≤ 5 years prior to the study entry
•Inmates (in accordance with 45 CFR 46.306) or mentally disabled individuals
•BI-RADS® Category 6 (e.g., for which the mammogram was performed for the purpose of planning cancer therapy)
•BI-RADS® Category 4 or 5 without confirming pathology reports will be considered incomplete
•Subjects with mammograms that lack the required views or with views judged to be technically inadequate will be considered incomplete and the cases will not be considered for the MRMC reader studies
•Subjects being accrued from the screening population who know that they will not be in the United States or available for follow up mammograms in one year.

Locations (1)

Siemens Medical Solutions

Malvern, Pennsylvania, United States

Key Dates

Start Date

May 1, 2011

Primary Completion Date

May 1, 2014

Completion Date

May 1, 2014

Last Updated

August 7, 2020

Enrollment

764

ACTUAL participants

Conditions

Breast Cancer

Interventions

SIEMENS INSPIRATION DIGITAL BREAST TOMOSYNTHESIS (DBT) SYSTEM

DEVICE

Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors

NCT05372640

Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8+6 more

View study

RECRUITINGNA

Safety and Feasibility of Robotic SP Nipple Sparing Mastectomy

NCT05245812

Breast CancerHigh Risk of Breast Cancer

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: August 7, 2020Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Evaluation of the Efficacy of Digital Breast Tomosynthesis Imaging

Inclusion Criteria

Exclusion Criteria

Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors

Safety and Feasibility of Robotic SP Nipple Sparing Mastectomy

Testing the Addition of an Anti-cancer Drug, ASTX727 (Cedazuridine, Decitabine), to Chemotherapy (Paclitaxel) and Immunotherapy (Pembrolizumab) for Metastatic Triple-Negative Breast Cancer

Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial

Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations

A Study of the Impact of Endocrine Therapy on Surgical Outcomes in People With Breast Cancer